Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA likely to reduce psyllium maximum daily dose to 14 g in upcoming laxative monograph.

This article was originally published in The Tan Sheet

Executive Summary

PSYLLIUM MAXIMUM DAILY DOSE EXPECTED TO BE REDUCED TO 14 G in the upcoming final monograph for OTC laxative products, according to FDA. In separate July 28 letters to the Nonprescription Drug Manufacturers Association and the U.S. Pharmacopeia, the agency said it plans to reduce the maximum daily dose for psyllium preparations from the 30 g recommended in the tentative final monograph to 14 g. FDA said the decision is based on industry comments as well as a review of the scientific literature and the psyllium-containing OTC laxatives currently on the market.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084160

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel